How does QURE N's PS Ratio compare to its peers?

QURE N is expensive based on its Price-To-Sales Ratio (30.2x) compared to the peer average (8x).

How does QURE N's PS Ratio compare vs other companies in the Global Biotechs Industry?

QURE N is expensive based on its Price-To-Sales Ratio (30.2x) compared to the Global Biotechs industry average (9x).

What is QURE N's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate QURE N's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of QURE N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

QURE N (MX$305) is trading below our estimate of [[fair value]] (MX$1056.61)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

QURE N Stock Overview

Develops treatments for patients suffering from rare and other devastating diseases. More details

QURE N fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 71.1% below our estimate of its fair value

Revenue is forecast to grow 39.24% per year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

Capture your thoughts, links and company narrative

uniQure N.V. Competitors

Zhejiang Orient Gene Biotech

SHSE:688298

CN¥5.9b

Vir Biotechnology

NasdaqGS:VIR

US$1.0b

CanSino Biologics

SEHK:6185

HK$11.3b

Seegene

KOSDAQ:A096530

₩1.0t

Price History & Performance

Summary of share price highs, lows and changes for uniQure
Historical stock prices
Current Share Price	US$305.00
52 Week High	US$305.00
52 Week Low	US$305.00
Beta	0.86
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-8.27%

Recent updates

Shareholder Returns

	QURE N	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how QURE N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how QURE N performed against the MX Market.

Price Volatility

Is QURE N's price volatile compared to industry and market?
QURE N volatility
QURE N Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: QURE N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine QURE N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	480	Matt Kapusta	www.uniqure.com

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.

uniQure N.V. Fundamentals Summary

How do uniQure's earnings and revenue compare to its market cap?
QURE N fundamental statistics
Market cap	Mex$17.50b
Earnings (TTM)	-Mex$4.85b
Revenue (TTM)	Mex$578.94m

30.2x

P/S Ratio

-3.6x

P/E Ratio

Is QURE N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QURE N income statement (TTM)
Revenue	US$28.59m
Cost of Revenue	US$182.66m
Gross Profit	-US$154.08m
Other Expenses	US$85.43m
Earnings	-US$239.50m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.91
Gross Margin	-538.97%
Net Profit Margin	-837.80%
Debt/Equity Ratio	856.0%

How did QURE N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 18:06
End of Day Share Price	2024/12/11 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

uniQure N.V. is covered by 31 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Madhu Kumar	Baird
James Birchenough	BMO Capital Markets Equity Research
Madhu Kumar	B. Riley Securities, Inc.